Company: SVREW
Filing Date: 2025-03-21
Form Type: 20-F
Source: 0001013762-25-001028
Chunk: 20

Company: SaverOne 2014 Ltd.
Filing Date: 2025-03-21
Form: 20-F
Item: Item 3
Chunk 20
---
 negatively impact our ability
to conduct our business in the manner and on the timelines presently planned. The extent to which the COVID-19 pandemic may continue
to impact our business and financial performance will depend on future developments, which are highly uncertain and cannot be predicted
with confidence, including the scope and duration of the pandemic, the extent and effectiveness of government restrictions and other
actions, including relief measures, implemented to address the impact of the pandemic, and resulting economic impacts. We are unable
to determine the extent of the impact of the pandemic on our operations and financial condition going forward. These developments are
highly uncertain and unpredictable and may materially adversely affect our financial position and results of operations.

Risks
Related to Our Intellectual Property

If
we are unable to obtain and maintain effective intellectual property rights for our products, we may not be able to compete effectively
in our markets.

Historically,
we have relied on trade secret protection and confidentiality agreements to protect the intellectual property related to our technologies
and products. Since June 2015, we have also sought patent protection for certain of our products. Our success depends in large part on
our ability to obtain and maintain patent and other intellectual property protection in the United States and in other countries with
respect to our proprietary technology and new products.

We
have sought to protect our proprietary position by filing patent applications in Israel, the United States and in other countries, with
respect to our novel technologies and products, which are important to our business. Patent prosecution is expensive and time consuming,
and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner.
It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to
obtain patent protection.

We
have a growing portfolio of seven issued U. S. patents and four pending U. S. applications, two granted European patents validated in United
Kingdom, Germany, France, Italy, Spain, and Sweden, two granted Chinese patents, one granted Israeli patent, four pending applications
with the Israeli Patent Office, and three pending applications in Europe. In Israel, three of our patent applications have been allowed
and subsequently opposed by a third-party. Further to the evidence submitted by the opponent, we are now requested to submit evidence
by March 20, 2025, and the proceedings are still ongoing. It is difficult to assess at this time the likelihood of success in the opposition.
Opposition proceedings